# Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Canonical URL: https://biopharmsignal.com/news/TPST/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors
Ticker: TPST
Company: Tempest Therapeutics
Source: Tempest Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.tempesttx.com
## Summary

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr.

## Article Body
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr.
## Recent Company News
- 2026-06-25 13:46 EST — [Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors](https://biopharmsignal.com/news/TPST/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors) — Source: Tempest Therapeutics
- 2026-06-25 13:46 EST — [Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds](https://biopharmsignal.com/news/TPST/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds) — Source: Tempest Therapeutics
- 2026-06-25 13:46 EST — [Tempest Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/TPST/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Tempest Therapeutics
- 2026-06-25 13:46 EST — [Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets](https://biopharmsignal.com/news/TPST/tempest-announces-closing-of-strategic-acquisition-of-dual-targeting-car-t-assets) — Source: Tempest Therapeutics
- 2026-06-25 13:46 EST — [Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets](https://biopharmsignal.com/news/TPST/tempest-lays-out-strategic-plan-to-advance-recently-acquired-dual-targeting-car-t-assets) — Source: Tempest Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)